• Pre-Hospital Mobile Stroke Unit (MSU) Study launched in Melbourne to evaluate EMVision's First Responder Brain Scanner
• Study aims to assess usability, workflow integration and collect data for AI-enhanced stroke detection algorithms
• Collaboration with Australian Stroke Alliance, Ambulance Victoria and Royal Melbourne Hospital

EMVision Medical Devices Limited (ASX:EMV) has announced the commencement of its Pre-Hospital Mobile Stroke Unit Study evaluating the Company's First Responder Brain Scanner. The study is a staged workflow assessment and data collection study of EMVision's First Responder Brain Scanner in the Melbourne Mobile Stroke Unit (MSU) - one of only ~45 MSUs globally, and one of only two in Australia. Stage 1 of the study will evaluate the usability and workflow integration of the EMVision First Responder scanner within the MSU environment in the hyperacute stroke phase. Stage 2 will utilize the production equivalent First Responder device, collecting EMVision scan data matched with ground-truth radiological imaging (Head CT) to support the advancement and evaluation of EMVision's AI-enhanced stroke detection algorithms. The study is designed to deliver the highest quality pre-hospital data by conducting both the EMVision First Responder and ground-truth MSU CT scan at the same time. The study is being conducted in collaboration with the Australian Stroke Alliance, Ambulance Victoria and the Royal Melbourne Hospital. The outcomes will generate critical workflow and patient data that will help refine EMVision's device and accelerate its substantial equivalence testing, clinical and commercial pathways.

EMVision's First Responder device seeks to provide a more scalable solution to enable broader access to pre-hospital models of stroke care, complementing the clinical benefits of Mobile Stroke Units. The Pre-Hospital MSU Study represents an important step toward enabling rapid, portable neurodiagnostic capabilities for stroke in pre-hospital settings.